ERR3262565
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.300
- KRAS_SIGNALING_DN+0.300
- PANCREAS_BETA_CELLS+0.300
- SPERMATOGENESIS+0.300
- MYC_TARGETS_V1+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- G2M_CHECKPOINT+0.100
- ANDROGEN_RESPONSE+0.000
- ESTROGEN_RESPONSE_EARLY+0.000
- ESTROGEN_RESPONSE_LATE+0.000
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.700
- IL6_JAK_STAT3_SIGNALING-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- COMPLEMENT-0.500
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.500
- APOPTOSIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0511 | Med | Medulloblastoma | 0.875 |
| 2 | BS_FEV5A0HN | high-grade glioma | — | 0.874 |
| 3 | SRR10900563 | — | — | 0.873 |
| 4 | BS_BA6AZWB3 | medulloblastoma | — | 0.871 |
| 5 | TCGA-56-7221-01A-11R-2045-07 | — | cohortSQ2 | 0.864 |
| 6 | BS_W9AT0MR7 | medulloblastoma | — | 0.863 |
| 7 | BS_A14Z8BBK | medulloblastoma | — | 0.861 |
| 8 | TCGA-37-A5EN-01A-21R-A26W-07 | — | cohortSQ2 | 0.859 |
| 9 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.857 |
| 10 | BS_61E80SD6 | medulloblastoma | — | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.100 | Inavolisib | — uncovered |